The Neuroimaging Core has experienced considerable growth and continuing productivity during the past funding cycle. The Core supports all routine clinical and research ADC neuroimaging examinations, funded imaging projects and scientific collaborations, and multi-institutional neuroimaging training. The Core has contributed to image acquisition, image registration, anatomical validation, and image analysis projects. Image analysis methods were extended from human imaging to transgenic mouse brain. Core resources were directly responsible for many ADC accomplishments by contributing to research teams innovative image analysis software and making the applications user friendly. Core's growth is in large measure attributable to the think tank atmosphere created by a dedicated multidisciplinary faculty. The proposed plan aims to continue Core's hardware and software support for research projects, development and validation of new MRI and PET imaging modalities for in vivo functional human imaging, routine post mortem MRI imaging, customized mouse imaging protocols that includes histological validation, uniform acquisition, investigator training, and quality control of all studies. These activities will improve the accuracy of AD diagnosis and lead to mechanistic models of brain changes in normal aging and dementia.
The proposed plan for the Neuroimaging Core is to continue support for the clinical scanning of ADC patients and for research projects. The cores mission includes: development and validation of MRI and PET imaging modalities for in vivo functional human imaging. This is realized by routine post mortem MRI imaging with histological validation of imaging findings, correlated CSF studies, customized mouse MRI imaging protocols, uniform longitudinal scan acquisitions, investigator training, novel image analysis software development, and quality control of all studies. These activities will continue to improve the accuracy of the advance AD diagnosis and contribute to identifying and testing mechanisms of brain change in normal aging and dementia.
|Galvin, James E; Tolea, Magdalena I; George, Nika et al. (2014) Public-private partnerships improve health outcomes in individuals with early stage Alzheimer's disease. Clin Interv Aging 9:621-30|
|Grill, Joshua D; Galvin, James E (2014) Facilitating Alzheimer disease research recruitment. Alzheimer Dis Assoc Disord 28:1-8|
|Salloway, Stephen; Sperling, Reisa; Fox, Nick C et al. (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 370:322-33|
|Mosconi, Lisa; Murray, John; Tsui, Wai H et al. (2014) Brain imaging of cognitively normal individuals with 2 parents affected by late-onset AD. Neurology 82:752-60|
|Sabharwal, Priyanka; Wisniewski, Thomas (2014) Novel immunological approaches for the treatment of Alzheimer's disease. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi 14:139-151|
|Zhang, Ying; Shi, Zhihong; Liu, Mengyuan et al. (2014) Prevalence of cognitive impairment no dementia in a rural area of Northern China. Neuroepidemiology 42:197-203|
|Butler, Tracy; Zaborszky, Laszlo; Pirraglia, Elizabeth et al. (2014) Comparison of human septal nuclei MRI measurements using automated segmentation and a new manual protocol based on histology. Neuroimage 97:245-51|
|Reisberg, Barry; Monteiro, Isabel; Torossian, Carol et al. (2014) The BEHAVE-AD assessment system: a perspective, a commentary on new findings, and a historical review. Dement Geriatr Cogn Disord 38:89-146|
|Iulita, M Florencia; Do Carmo, Sonia; Ower, Alison K et al. (2014) Nerve growth factor metabolic dysfunction in Down's syndrome brains. Brain 137:860-72|
|Jessen, Frank; Amariglio, Rebecca E; van Boxtel, Martin et al. (2014) A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement 10:844-52|
Showing the most recent 10 out of 189 publications